James R Sulat Net Worth & Insider Trades

James R Sulat - Director, Arch Therapeutics, Inc

As of June 23, 2020

What is James R Sulat's Net Worth?

The current estimated net worth of Arch Therapeutics, Inc's Director, James R Sulat, is estimated to be about $10.41M . James R Sulat owns about 1,746,813 units of Arch Therapeutics, Inc common stock. In the last 5 years at Arch Therapeutics, Inc, James R Sulat has sold an estimated value of $0 worth.

What is James R Sulat's Past Insider Trading?

James R Sulat's largest purchase order was 454,546 units , worth over $81.82K on June 23, 2020. In total, James R Sulat has made about 8 transactions over 5 years of their time at Arch Therapeutics, Inc. James R Sulat usually trades in May and July, with the busiest year in 2016 and 2018.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What are Arch Therapeutics, Inc's Past Insider Trades?

Arch Therapeutics, Inc's most recent insider trade came on September 8, 2023 by Michael Abrams who bought 10,292 units worth $2.83K . In the last 7 years, insiders at Arch Therapeutics, Inc have bought an estimated value of $0 worth of shares. Insider trading is most common in July, with the busiest year in 2022. The most active traders at the company are Terrence Norchi, PRESIDENT AND CHIEF EXECUTIVE,  James Sulat, Director,  and Avtar S Dhillon, Director .

Arch Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...